Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361822 | 0.77 | — | — | |
| SCHEMBL2787025 | 0.75 | — | — | |
| SCHEMBL10574839 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL2699935 | 0.73 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2ADRA2AADRA2CADRA1D | |
| SCHEMBL27655847 | 0.73 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL814595 | 0.72 | — | — | |
| SCHEMBL10569996 | 0.72 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28733425 | 0.71 | FDPS (0.43) | ALDH1A1SMN1; SMN2ADRA2AADRA2CADRA1D | |
| SCHEMBL6647148 | 0.71 | JAK2 (0.40) | ALDH1A1SMN1; SMN2FDPS | |
| SCHEMBL7556283 | 0.69 | GDA (0.40) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102846617-B | The preparation method of 3-(butyl oxygen base)-2-pyrazine formyl ammonia and purposes | Institute of Toxicology and Drugs, Chinese Academy of Military Medical Sciences (CN) | 2016-01-13 | — | — | CN | disclosed |
| WO-2013139206-A1 | 3-OXO-3,4-DIHYDRO-2-PYRAZINE-FORMAMIDE DERIVATIVE, PHARMACEUTICAL COMPOSITION OF SAME, METHOD FOR PREPARING SAME, AND USE THEREOF | 中国人民解放军军事医学科学院毒物药物研究所 (CN) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013004092-A1 | 3-OXO-3, 4-DIHYDRO-2-PYRAZINEFORMAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF | 中国人民解放军军事医学科学院毒物药物研究所 (CN) | 2013-01-10 | — | — | WO | disclosed |
| CN-102850282-A | Preparation method and purpose of 3-alkoxy-substituent-2-pyrazinyl formamide compounds | INST PHARM & TOXICOLOGY AMMS | 2013-01-02 | — | — | CN | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| CN-102617491-A | 3-oxo-3,4-dihydro-2-pyrazinecarboxamide derivative, medicinal composition thereof and preparation method and application of 3-oxo-3,4-dihydro-2-pyrazinecarboxamide derivative | INST PHARM & TOXICOLOGY AMMS | 2012-08-01 | — | — | CN | disclosed |
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | IDENIX PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1898934-A1 | NUCLEOSIDES WITH NON-NATURAL BASES AS ANTI-VIRAL AGENTS | Idenix (Cayman) Limited (KY) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008005542-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC., (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007144686-A1 | NUCLEOSIDES WITH NON-NATURAL BASES AS ANTI-VIRAL AGENTS | IDENIX (CAYMAN) LIMITED (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | ALDH1A1 1919/4885SMN1; SMN2 1178/4885ADRA2A 4155/4885 |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | ALDH1A1 2008/4885SMN1; SMN2 769/4885ADRA2A 4102/4885 |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | PNP, NSUN2, NME2 | ALDH1A1 3538/4885SMN1; SMN2 432/4885ADRA2A 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.